Our top pick for
Building a portfolio
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Novo Nordisk A/S is a biotechnology business based in the US. Novo Nordisk A/S shares (NVO) are listed on the NYSE and all prices are listed in US Dollars. Novo Nordisk A/S employs 44,723 staff and has a trailing 12-month revenue of around 0.00.
|52-week range||$60.19 - $74.79|
|50-day moving average||$70.05|
|200-day moving average||$70.20|
|Wall St. target price||$81.03|
|Dividend yield||$9.1 (12.26%)|
|Earnings per share (TTM)||$2.91|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing Novo Nordisk A/S stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Novo Nordisk A/S's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Novo Nordisk A/S's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 25x. In other words, Novo Nordisk A/S shares trade at around 25x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Novo Nordisk A/S's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.4796. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Novo Nordisk A/S's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Novo Nordisk A/S's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $58.8 billion.
The EBITDA is a measure of a Novo Nordisk A/S's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$126.9 billion|
|Operating margin TTM||42.91%|
|Gross profit TTM||$106 billion|
|Return on assets TTM||25.17%|
|Return on equity TTM||69.7%|
|Market capitalisation||$170.7 billion|
TTM: trailing 12 months
There are currently 4.2 million Novo Nordisk A/S shares held short by investors – that's known as Novo Nordisk A/S's "short interest". This figure is 7% down from 4.6 million last month.
There are a few different ways that this level of interest in shorting Novo Nordisk A/S shares can be evaluated.
Novo Nordisk A/S's "short interest ratio" (SIR) is the quantity of Novo Nordisk A/S shares currently shorted divided by the average quantity of Novo Nordisk A/S shares traded daily (recently around 898756.47558386). Novo Nordisk A/S's SIR currently stands at 4.71. In other words for every 100,000 Novo Nordisk A/S shares traded daily on the market, roughly 4710 shares are currently held short.
However Novo Nordisk A/S's short interest can also be evaluated against the total number of Novo Nordisk A/S shares, or, against the total number of tradable Novo Nordisk A/S shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Novo Nordisk A/S's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Novo Nordisk A/S shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Novo Nordisk A/S shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Novo Nordisk A/S.
Find out more about how you can short Novo Nordisk A/S stock.
Dividend payout ratio: 52.52% of net profits
Recently Novo Nordisk A/S has paid out, on average, around 52.52% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.48% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Novo Nordisk A/S shareholders could enjoy a 2.48% return on their shares, in the form of dividend payments. In Novo Nordisk A/S's case, that would currently equate to about $9.1 per share.
Novo Nordisk A/S's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
Novo Nordisk A/S's most recent dividend payout was on 6 April 2021. The latest dividend was paid out to all shareholders who bought their shares by 25 March 2021 (the "ex-dividend date").
Novo Nordisk A/S's shares were split on a 5:1 basis on 8 January 2014. So if you had owned 1 share the day before before the split, the next day you'd have owned 5 shares. This wouldn't directly have changed the overall worth of your Novo Nordisk A/S shares – just the quantity. However, indirectly, the new 80% lower share price could have impacted the market appetite for Novo Nordisk A/S shares which in turn could have impacted Novo Nordisk A/S's share price.
Over the last 12 months, Novo Nordisk A/S's shares have ranged in value from as little as $60.1944 up to $74.7927. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Novo Nordisk A/S's is 0.2996. This would suggest that Novo Nordisk A/S's shares are less volatile than average (for this exchange).
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Everything we know about the Krispy Kreme IPO, plus information on how to buy in.
Everything we know about the Day One Biopharmaceuticals IPO, plus information on how to buy in.
Everything we know about the Enact Holdings IPO, plus information on how to buy in.
Everything we know about the Solid Power IPO, plus information on how to buy in.
Everything we know about the Paymentus Holdings IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Qiniu Limited IPO, plus information on how to buy in.
Everything we know about the Ximalaya IPO, plus information on how to buy in.
Everything we know about the Zeta Global Holdings Corp IPO, plus information on how to buy in.
Everything we know about the Paycor HCM IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.